These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 8861994)

  • 1. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine.
    Siegel JE; Weinstein MC; Russell LB; Gold MR
    JAMA; 1996 Oct 23-30; 276(16):1339-41. PubMed ID: 8861994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recommendations of the Panel on Cost-effectiveness in Health and Medicine.
    Weinstein MC; Siegel JE; Gold MR; Kamlet MS; Russell LB
    JAMA; 1996 Oct; 276(15):1253-8. PubMed ID: 8849754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine.
    Russell LB; Gold MR; Siegel JE; Daniels N; Weinstein MC
    JAMA; 1996 Oct; 276(14):1172-7. PubMed ID: 8827972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I.
    Hay JW; Smeeding J; Carroll NV; Drummond M; Garrison LP; Mansley EC; Mullins CD; Mycka JM; Seal B; Shi L
    Value Health; 2010; 13(1):3-7. PubMed ID: 19874571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine.
    Sanders GD; Neumann PJ; Basu A; Brock DW; Feeny D; Krahn M; Kuntz KM; Meltzer DO; Owens DK; Prosser LA; Salomon JA; Sculpher MJ; Trikalinos TA; Russell LB; Siegel JE; Ganiats TG
    JAMA; 2016 Sep; 316(10):1093-103. PubMed ID: 27623463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
    Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
    Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is the societal perspective in cost-effectiveness analysis useful for decision makers?
    Russell LB; Fryback DG; Sonnenberg FA
    Jt Comm J Qual Improv; 1999 Sep; 25(9):447-54. PubMed ID: 10481813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Future Directions for Cost-effectiveness Analyses in Health and Medicine.
    Neumann PJ; Kim DD; Trikalinos TA; Sculpher MJ; Salomon JA; Prosser LA; Owens DK; Meltzer DO; Kuntz KM; Krahn M; Feeny D; Basu A; Russell LB; Siegel JE; Ganiats TG; Sanders GD
    Med Decis Making; 2018 Oct; 38(7):767-777. PubMed ID: 30248277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can Economic Model Transparency Improve Provider Interpretation of Cost-effectiveness Analysis? Evaluating Tradeoffs Presented by the Second Panel on Cost-effectiveness in Health and Medicine.
    Padula WV; McQueen RB; Pronovost PJ
    Med Care; 2017 Nov; 55(11):909-911. PubMed ID: 29028753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Treatment Options for Neuropathic Pain: a Systematic Review.
    Ruiz-Negrón N; Menon J; King JB; Ma J; Bellows BK
    Pharmacoeconomics; 2019 May; 37(5):669-688. PubMed ID: 30637713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reporting Quality of Cost-Effectiveness Analyses Conducted in Saudi Arabia: A Systematic Review.
    Algarni MA; Alqahtani SS; Alshehri AM; Alanazi AS; Alzahrani MS; Alolayan SO; Alzarea AI
    Value Health Reg Issues; 2021 Sep; 25():99-103. PubMed ID: 33848894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival time outcomes in randomized, controlled trials and meta-analyses: the parallel universes of efficacy and cost-effectiveness.
    Guyot P; Welton NJ; Ouwens MJ; Ades AE
    Value Health; 2011; 14(5):640-6. PubMed ID: 21839400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding costs and cost-effectiveness in critical care: report from the second American Thoracic Society workshop on outcomes research.
    Am J Respir Crit Care Med; 2002 Feb; 165(4):540-50. PubMed ID: 11850349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Has the time come for cost-effectiveness analysis in US health care?
    Bryan S; Sofaer S; Siegelberg T; Gold M
    Health Econ Policy Law; 2009 Oct; 4(Pt 4):425-43. PubMed ID: 19203399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analyses in orthopaedic sports medicine: a systematic review.
    Nwachukwu BU; Schairer WW; Bernstein JL; Dodwell ER; Marx RG; Allen AA
    Am J Sports Med; 2015 Jun; 43(6):1530-7. PubMed ID: 25125693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costing and perspective in published cost-effectiveness analysis.
    Neumann PJ
    Med Care; 2009 Jul; 47(7 Suppl 1):S28-32. PubMed ID: 19536023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.